CureVac N.V. has experienced a 3% increase in its shares premarket on Friday following the release of new data from a trial of its mRNA COVID-19 vaccine candidates, developed in collaboration with GSK PLC. The investigational monovalent shot and bivalent vaccine candidate have successfully elevated antibody levels and demonstrated good tolerability across various dosages, according to CureVac's statement. Notably, all three dose levels tested were lower than those currently used in mRNA-based COVID vaccines approved in the U.S. and European Union. CureVac is currently engaged in advanced discussions with regulators to pave the way for a phase 3 study of the vaccine candidates. Should they receive approval, these shots would become competitors to mRNA Covid vaccines already available from Moderna Inc. and Pfizer Inc.
Over the past 12 months, CureVac shares have experienced a decline of 34%, while the S&P 500 has shown a gain of 23%. GSK's American depositary receipts also saw a premarket decline of 0.5% on Friday, but have achieved an increase of 13.3% over the past year.
Our Latest News
Virgin Galactic Announces Passengers for First Private Astronaut Flight
Virgin Galactic reveals the passengers for its historic first private astronaut flight, featuring an 80-year-old Olympian and a mother-daughter duo. The flight...
Charles Schwab Reports Slower Asset Growth in July
Charles Schwab saw a decrease in asset growth in July due to advisors leaving TD Ameritrade. This article discusses inheritance challenges, optimal portfolio di...
Zara Apologizes for Controversial Advertising Campaign
Zara faces criticism for images that some believe reference Israel's conflict with Hamas. The company apologizes and clarifies their original artistic intention...